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Abstract Using our in vitro model of normal B cell infection that 
functions with low doses of HIV but requires virus opsonization 
by seropositive patient serum, and complement, we analyzed what 
receptors allowed virus entry. Here, we show that HIV infection 
of B cells occurs through 2 major receptors: the CD4 antigen and 
the CRIICR2 complex. These 2 pathways work independently 
since a complete inhibition of virus entry requires both CD4 and 
CD211CD35 blockade on CD4 d~ tonsiHar B cells whereas only 
the latter is critical on CD4-negative B cells. 
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I. Introduction 
Although in vivo infection of B lymphocytes remains to es- 
tablish, B lymphocyte phenotype and functions are strongly 
impaired in human immunodeficiency virus (HIV)-infected pa- 
tients. This impairment, appearing early in the course of the 
disease, alters B cells from the periphery as well as those located 
in secondary lymphoid organs [1,2]. In particular, Casareale t 
al. (1984) obtained HIV- and EBV-coinfected B cell lines from 
peripheral blood lymphocyte cultures of seropositive patients, 
evidencing HIV infection of EBV-positive B cells and subse- 
quent ex vivo immortalization [3]. In 1991, a HIV ÷ B cell line 
was obtained after in vitro HIV infection of normal B lympho- 
cytes from EBV-seropositive normal donors [4]. In addition, 
the expression of HIV provirus in lymphoma cells of seroposi- 
tive patients [5,6] has been reported and in situ hybridization 
has allowed the detection, by Prevot et al., of HIV mRNA in 
polymorphic B cell proliferation of 2 seropositive patients and 
in numerous B cell lymphomas [7]. 
In 1993, we have shown, for the first time, that normal B 
lymphocytes are indeed susceptible to in vitro HIV infection 
and produce infectious virus in culture [8]. This productive 
infection requires opsonization of HIV, with antibodies from 
asymptomatic patient and human complement, and virus entry, 
thus, involves complement receptors (CRs) type 1 (CR 1/CD35) 
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and 2 (CR2/CD21). CD35 binds 3 complement fragments (C3b, 
C4b and iC3b) and is able to cleave C3 into iC3b and C3dg, 
which are ligands for CD21, showing a functional link between 
these 2 CRs [9,10]. In contrast, Zhang and Henderson demon- 
strated that tonsil B cells do express CD4 mRNA and, although 
CD4 molecule remains undetectable by flow cytometry, it al- 
lowed infection by antibody-free virion. Indeed, the infection 
was strongly decreased by CD4-blocking, suggesting that CD4 
is a critical mediator for unopsonized HIV-I infection of sur- 
face CD4-negative B cells [11]. Recently, infection of CD40 plus 
IL4-activated normal B cells by high dose of HIV (multiplicity 
of infection = 1) have been demontrated in the absence of de- 
tectable CD4 expression [12]. 
HIV infection results in a strong activation, by HIV and 
HIV-circulating-immune-complexes [13,14], of both classical 
and alternative complement pathways [15,16]. In spite of this 
activation and of virus opsonization, with anti-HIV antibodies 
and complement or complement only, HIV seems to be pro- 
tected from human complement lytic action [17,10]. Non-lysed 
opsonized HIV may, thus, bind to complement receptors and 
infect CRs-bearing cells, as described on T cell lines [18], mon- 
ocytic cell lines [19 21], B cell lines [22-24], thymocytes [25], 
primary monocytes [21], peripheral and tonsil B lymphocytes 
[8]. 
The presence of anti-HIV antibodies and complement cover- 
ing virions leads to an enhanced infection (C'-ADE infection) 
of targeted cells, characterized by a more rapid apparition of 
infection stigmas (giant cells, syncytia, cell death) [26,27], and 
is CRs-dependent and/or CD4-dependent, according to the cel- 
lular model. Indeed, OKB7 monoclonal antibody (anti-CD21) 
blocks C'-ADE both in CR2 + CD4 ÷ MT2 cells [18] and in CR2 ÷ 
CD4- IC-I cells [23]. Blocking of CR3 in CR3 + CD4 ÷ U937 cell 
line also allows inhibiton of C'-ADE infection [19]. If these 
studies clearly showed that CRs are involved in enhanced cell 
infection, the role of CD4 remains unclear in this infection 
process. Some studies performed on different CD4 ÷ cells re- 
ported a clearcut inhibition of infection by CD4-blocking 
[18,23], thus suggesting that CD4 is also required for C'-ADE 
cell infection, whereas other studies, performed with low doses 
of complement opsonized virus, described an enhancement of
infection of MT2 [28] and U937 cells [19,20], in a CD4-inde- 
pendent manner. Taken as a whole, these data suggest that the 
respective roles of CD4 and CRs in HIV infection are variable 
according to experimental model. 
While normal B lymphocyte infection has been demonstrated 
in vitro, little is known about mechanisms of HIV entry into 
these cells. Here, we present data on the respective role of CRs 
type 1 and 2, and CD4 molecule, in opsonized HIV entry in 
normal B lymphocytes. 
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2. Materials and methods 
2.1. B cell source and isolation 
B lymphocytes were isolated from tonsils of HIV-seronegative chil- 
dren with chronic tonsillitis. After tonsil dilaceration i isotonic NaCI 
solution, cell suspensions contain approximately 70% of T cells and 
30% of B cells. B cells were depleted from T cells by rosetting with 
aminoethyl-isothiouronium bromehydrate-treated sheep erythrocytes 
as previously described in [8]. After the first cycle of rosetting, non-T 
cell fraction was extensively washed (1700 and 750 x g, 5 min, 4°C) and 
centrifuged on a 40% Percoll layer (Pharmacia Bioprocess, Sweden) to 
discard monocytes-macrophages and follicular dendritic ells (25 min 
at 1200 x g and 4°C). Pellets, containing B cells, were then submitted 
to a second cycle of rosetting and highly purified B cells were frozen 
and stored in liquid nitrogen until use. 
2.2. Cultures 
All cultures were performed in RPMI 1640 medium containing 2 mM 
L-glutamine, 100 pg/ml streptomycin, 100 U/ml penicillin, 1 mM so- 
dium pyruvate, 10 mM HEPES buffer and 10% heat-inactivated fetal 
calf serum (FCS) (complete medium; Gibco BRL). In some experi- 
ments, purified B lymphocytes were stimulated by phorbo112-myristate 
13-acetate (PMA) or by phorbol 12,13-dibutyrate (PDB) at a concen- 
tration of 5 ng/ml in complete medium for 2 days before HIV infection 
(see infection protocol). Cells were cultured in 96-well flat-bottomed 
plates (Costar, Cambridge, MA) at 10 6 cells/ml in complete medium 
supplemented with IL2 (50 U/ml) and IL4 (25 ng/ml). Unstimulated 
infected B cells were cultured in the presence of 1 ng/ml PMA in 
IL2-and IL4-supplemented medium. 
2.3. Infection protocol 
In all experiments, the source of virus was the Lai strain of HIV-1 
(provided by Dr. F. Barr6-Sinoassi, Paris, France) which always grew 
in primary lymphocyte cultures. Infections were performed with 50 
tissue culture infective doses 50% (TCIDs0)/million cells, as determined 
by a limiting dilution microtiter assay on MT2 cells [8]. Before cell 
infection, virus was opsonized for 40 min at 4°C with HIV-positive 
heat-inactivated serum (1116) and normal non-heated serum as a source 
of complement (1/12), in a final volume of 100/zl. For infection, cells 
(5 x 106 cells/ml) were incubated with opsonized virus suspension at 
37°C for 40 rain and, after 3 washes, cells were cultured in triplicates 
as described above. 
2.4. Reagents and blocking experiments 
Four monoclonal ntibodies (mAbs) to the CD4 molecule were used 
to block CD4-HIV-binding: OKT4a (IgG2a, Ortho Diagnostic Sys- 
tem), Q4120 (IgG1, generously provided by Dr. Q. Sattentau through 
the MRC AIDS directed program), NaTh/i (IgG1, obtained through 
our participation tothe 5th International Workshop on Human Leuko- 
cyte Differentiation Antigens, Boston 1993; 5th IWHLDA) and anti- 
leu3a (IgGl, Becton Dickinson). Three mAbs directed to CR1 (CD35), 
J3D3, J3B11 and J8B10 (all IgG1) were a kind gift of Dr. E. Fischer 
and Professor M.D. Kazatchkine (Paris, France) and were pooled to 
obtain a complete blockade of CR1 function. The OKB7 mAb (IgG1; 
Ortho Diagnostic System) was used to block CR2 (CD21) function. 
F97-6B3 mAb (kind gift of Dr. R Poncelet, Marseille, France), another 
anti-CD21 mAb which is not directed to the C3dg-binding site, was also 
used. Two mAbs directed to CD5, which have no implication in opson- 
ized HIV infection of B lymphocytes [8], were obtained through the 5th 
IWHLDA and used as controls: ICO-80 (lgG1) and AS0 (IgG2a). 
Recombinant CD4 coupled to HSA (CD4-HSA) was provided by 
Rh6ne Poulenc Rorer. 
For blocking experiments, 6.5 x 105 B lymphocytes were incubated 
in complete medium with saturating concentrations of specific mAbs 
for CD4, CD21, CD35 or CD5, alone or in combination, for 1 h at 4°C. 
Infection was then performed as described above. After 3 washes, cells 
were resuspended in culture medium and each treatment was performed 
in triplicates in 96-well flat-bottomed plates as indicated above (see 
section 2.2.). Recombinant CD4 coupled to HSA was also used to 
inhibit HIV entry in B lymphocytes. To block infection, CD4-HSA was 
mixed with virus during opsonization for 40 rain at 4°C. 
2.5. Detection of p24 by antigen capture assay 
Major viral core protein p24 production was assessed in culture 
supernatants using an ELISA kit (DuPont de Nemours, Les Ulis, 
France) as specified by the manufacturer. In all experiments, infection 
with heat-inactivated opsonized virus was performed, as negative con- 
trol (mock infection), to quantify residual antigen amounts. Each p24 
quantitation then included the subtraction of mock-infected control 
p24 results (between 0-10 pg/ml according to experiments). 
2.6. Cell Immunostaining and flow cytometry 
Mabs used to stain B cells were directed to CD3 (anti-Leu4a, IgG1, 
Becton Dickinson), CD4 (anti-Leu3a, IgG1, Becton Dickinson), CD14 
(RMO52, IgG1, Immunotech), CD19 04-119, IgG1, Immunotech), 
CD20 (BB6, IgM, Immunotech), CD21 (BL13, IgG1, Immunotech) 
and CD35 (J3D3, IgG1, Immunotech). We also used the 12BI antibody 
which recognizes dendritic reticulum cells in the germinal center (GC) 
of lymph nodes, spleen and tonsils (IgG2a, Immunotech). 
We used mouse IgG1, IgG2a or IgM monoclonal antibodies (ICN, 
Costa Mesa, CA) as controls. 
To avoid non-specific binding, B cells (5 x 105/test) were incubated 
for 1 h at 4°C in PBS containing 1% bovine serum albumin (Fraction 
V, Sigma), 0.1% NaN3 (incubation medium) and 10% normal human 
heat inactivated AB ÷ serum. Cells were then washed and incubated for 
30 min at 4°C in 50 pl incubation medium containing a saturating 
concentration f non-fluorescent mouse monoclonal ntibody directed 
to a specific molecule. After 2 washes with incubation medium, staining 
of cells was revealed by a second incubation (30 min at 4°C) with 
FITC-conjugated goat anti-mouse Ig F(ab')2 fragments (1/30) (Immu- 
notech, Marseille, France). After washes, cells were fixed in PBS con- 
taining 1% paraformaldehyde. Immunostaining analysis was per- 
formed on gated viable B lymphocytes, using a FACScan flow cytom- 
eter (Becton Dickinson, San Jos6, CA). 
To determine the number of a specific molecule xpressed on cell 
surface, 2 batches of beads were utilized: (1) low expressions were 
determined with a QIFI-Low kit (Biocytex, Marseille, France); and (2) 
high expressions with a QIFI-Kit kit (DAKO, France). QIFI-Low kit 
was especially designed by Biocytex for the quantitation of weakly 
expressed surface antigens, by using murine monoclonal antibodies, 
and consists in blank beads and beads coated with 180 to 23,000 anti- 
genic sites. QIFI-Kit allows to quantitate surface antigens within a 
5,500 to 640,000 sites/cell density range. 
3. Results 
3.1. Purity of B cell suspensions 
Each B cell suspension was tested for the expression of 
CD19, CD3, CD4, 12B1 and CD14. In all cases, the percentage 
of CD19 ÷ B cells was higher than 97% and that of CD3 + cells 
and CD14 ÷ cells were lower than 1 and 0.5%, respectively. As 
expected, no 12B1 + cells were recovered in our B cell suspen- 
sions (data not shown). When CD4 expression was assessed, 
less than 0.5% of total cells exhibited a high CD4 density, 
characteristic of CD4 ÷ T cells. In contrast, a weak CD4 expres- 
sion (CD4 dim) was observed on a variable fraction of tonsil lar 
B cells as shown in Fig. 1. 
3.2. Quantitative CD4 and complement receptor expression in B 
cell suspensions 
5 x 105 B cells were stained with antibodies to CD4, CD21 
and CD35 to quantify their surface expression by flow cytom- 
etry. As shown in Table 1, tonsil lar B ceils expressed high 
number  of CD21 and CD35 antigens. Nevertheless, a lower 
expression of these molecules was observed on 2-day PMA- or 
PDB-st imulated B lymphocytes (mean 7,000 and 27,000 sites/ 
cell for CD21 and CD35, respectively) than on freshly thawed 
B cells molecules (mean 28,000 and 60,000 sites/cell for CD21 
and CD35, respectively). As indicated before, a weak CD4 
surface expression was detectable on both unstimulated and 
2-day stimulated B lymphocytes i olated from 2 of 3 tonsils. On 
the two CD4 ÷ tonsillar suspensions after thawing, CD4 expres- 
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Fig. 1. B lymphocytes immunostainlngs Purity of B cell suspension was evaluated by immunostainings with monoclonal antibodies directed to CD3 
and CD19 and CD4 molecules. B cell suspensions was pure higher than 97% and contained less than ! % of CD3 + cells whatever state of activation. 
CD4 expression, variable following tonsils, was decreased with cell stimulation to all normal tonsil B lyrnphocytes used. No CD4 cell surface 
expression could be detected by flow cytometry with 1 tonsil only. 
sion was decreased by about 60% by phorbol ester stimulation. 
In all cases, CDI9  expression was upregulated by about 25% 
upon stimulation. 
3.3. CD4-HSA and CD4 antibodies differently inhibit HIV 
infection of CD4 aim and CD4- tonsillar B cells 
B cells were infected according to the C ' -ADE protocol and 
production of virions was assessed by measurement of p24 
antigen in culture supernatants harvested at day 5 postinfec- 
tion. In preliminary experiments, we have determined that max- 
imal inhibition of viral replication was reached with 5 pg/ml 
monoclonal antibodies directed against CD4, whereas 220 
pg/ml was required for optimal CD4-HSA inhibition (data not 
shown). The percentage of inhibition was calculated by 
comparison with p24 amounts in isotype-matched positive con- 
trols, except for CD4-HSA-treated cultures (Fig. 2). On these 
various experiments, p24 values ranged from 127 to 230 for 
unstimulated B cells and from 174 to 268 pg/ml for phorbol 
ester-stimulated B cells cultured in the absence of blocking 
antibodies. In the presence of control antibodies, these values 
varied less than 10%. 
On CD4 dim tonsillar B lymphocytes (BT254, BT286), we ob- 
tained an efficient while partial inhibition of viral replication 
with all CD4-blocking reagents. Inhibition was more pro- 
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Fig. 2. Blocking experiments HIV replication inhibition in non-stimu- 
lated (A) and 2-day stimulated (B) tonsil B lymphocytes by monoclonal 
antibodies and reagents used alone [OKT4a(I), Q4120 (2), NuTh/i (3), 
anti-Leu3a (4), HSA-CD4 (5), OKB7 (6), pool of anti-CD35 (7)] or in 
combination [OKB7 + pool of anti-CD35 (8), OKB7 + pool of anti- 
CD35 + OKT4a (9), OKB7 + pool ofanti-CD35 + Q4120 (10)]. B cells 
were incubated for 1 h at 4°C with 5 ,ug/ml of mAbs, infected with 
opsonized virus for 40 min at 37°C, and cultured. CD4-HSA was mixed 
to virus during opsonization step at the concentration of220/lg/ml. p24 
level were measured by ELISA at day 5 p.i. Percentage of inhibition is 
calculated by comparison with isotype-matched positive controls. Each 
plot is 1 experiment. CD4-negative (~)  and CD4 dim (o) tonsil B lym- 
phocytes are represented. Median of independent results is indicated by 
a black line. 
3.4. Complement receptors control a second pathway of HIV 
infection different from CD4 
Dose-dependent addition of CD35 and CD21 Ab have previ- 
ously established that maximal inhibition of tonsillar B ceils 
HIV infection was reached in the presence of 5/,tg/ml Ab. When 
CD35 and CD21 were independently blocked, viral production 
was decreased by 64% (median of 7 experiments) and 77% 
(median of 7 experiments) in freshly thawed B lymphocytes, 
and by 64 and 49% in 2-day stimulated normal B lymphocytes 
(median of 2 and 3 experiments, respectively). The simultane- 
ous addition of CD35 and CD21 Ab increased inhibition up to 
89% on unstimulated B cells (median of 5 experiments) and to 
71% on 2-day stimulated B cells (median of 2 experiments). 
CD21- and CD35-independent blocking performed with un- 
stimulated CD4- B lymphocytes (BT291) allowed a higher inhi- 
bition than that obtained with unstimulated CD4 dim B lympho- 
cytes (94 vs. 77% for CD21-blocking, and 87 vs. 64% for CD35- 
blocking). Moreover, when both CD21 and CD35 molecules 
were blocked, inhibition of viral replication reached 98.5% in- 
stead of 89% reached in CD4 dim tonsillar B cells. Interestingly, 
no additive effect of CD4 monoclonal antibody was then ob- 
served. 
On the other hand, the combination of CD4, CD35 and 
CD21 Ab allowed a powerful inhibition on freshly thawed as 
well as on stimulated CD4 a~m B lymphocytes, whatever the CD4 
antibody used (Q4120 or OKT4a). With OKT4a antibody this 
inhibition reached 92.5% (median of 2 experiments) and 96.5% 
(median of 2 experiments) with stimulated and unstimulated B 
cells, respectively. With Q4120 antibody, viral replication was 
inhibited by 89% with stimulated B cells and by 99% in unstim- 
ulated ones. 
4. Discussion 
Taken together, our data show that opsonized HIV-1/Lai 
entry in normal B lymphocytes involves 2 major pathways, the 
CD4 and the CR pathways. Whatever the activation state of 
B lymphocytes, blockage of CD4 induced a consistent inhibi- 
tion of viral replication. In unstimulated B cells, this inhibition 
occurred independently of the CD4 dim (BT254, BT286) or CD4- 
(BT291) phenotype of tonsil B cells but with a very low effi- 
ciency in the latter case (64-78 vs. 22%). This observation, that 
fits well with data from Zhang and Henderson showing inhibi- 
tion of free-virus entry by CD4 Ab on CD4-negative B cells [11 ], 
suggests that, while undetectable by flow cytometry, CD4 is 
indeed present on such B cells. 
nounced on 2-day stimulated B lymphocytes than on freshly 
thawed B cells (Fig. 2, B and A, respectively). In stimulated B 
lymphocytes, blocking of CD4 with OKT4a, Q4120, NuTh/i 
and anti-Leu3a, and CD4-HSA reached 90, 83.5, 86.5, 82 and 
90% of inhibition, respectively (median of 3, 4, 4, 2 and 2 
experiments), whereas in unstimulated B lymphocytes, these 
CD4-blocking Ab induced 78, 65, 64, 54 and 64% of inhibition, 
respectively (median of 5, 5, 5, 3 and 2 experiments). 
HIV infection of freshly thawed CD4- tonsil B lymphocytes 
(BT291) was weakly sensitive to CD4 mAb Q4120 effect (22% 
inhibition). Nevertheless, CD4-HSA treatment of virions dur- 
ing opsonization led to an inhibition similar to that obtained 
with CD4 dim tonsil B lymphocytes. 
Table 1 
Cytofluorometric quantitation of surface receptors on unstimulated 
and 2-day stimulated normal tonsil B lymphocytes 
Tonsil code CD4 CD21 CD35 
Unstimulated B lymphocytes 
BT254 516 31935 73902 
BT286 180 29054 64416 
BT291 0 24280 40527 
2-day stimulated B lymphocytes 
BT254 206 7345 31039 
BT286 65 6122 23055 
Results are expressed as the number of each specified molecule/cell, as
assessed with QIFI-Low (CD4 antigenic density) and QIFI-Kit (CD21 
and CD35 antigenic density) beads. 
C. Legendre t al./FEBS Letters 381 (1996) 227-232 231 
In contrast o the low efficiency of CD4 Ab to inhibit viral 
replication on BT291 CD4- cells, CD4--HSA-mediated inhibi- 
tion is as efficient on CD4- as on CD4 dim B lymphocytes. A 
major difference between CD4 Ab and CD4-HSA treatment 
was that CD4-HSA was directly incubated with virus during 
the opsonization step and would dissociate uncovalently inked 
gpl20-gp41 complexes [29]. Such a dissociation would, thus, 
lead to a gp 120-depleted virus, less efficient in infecting normal 
B cells in our experimental conditions, keeping in mind that 
gpl20 binds C3b fragments [30]. Taken together, these results 
clearly establish that CD4 molecules contribute to viral entry 
in normal B lymphocytes whether HIV is opsonized or not. 
Since total inhibition of viral replication was never reached on 
B cells with CD4-specific blocking reagents, one can speculate 
that other receptor molecules exist. 
Extending our previous data [8], we showed that complement 
receptors type 1 (CD35) and 2 (CD21) constitute a second 
infection pathway. Indeed, viral replication was decreased by 
up to 77 and 64% by the independent blockade of these CRs 
with unstimulated and 2-day stimulated cells, respectively, and 
inhibition reached up to 89 and 71% in the presence of CD35 
and CD21 Ab with unstimulated and 2-day stimulated cells, 
respectively. Of note, F97-6B3 (SB2) mAb, another anti-CD21 
antibody, which is directed against he short consensus repeats 
(SCR) 5 to 8, different from the C3dg-binding site (J.-E Aubry, 
pers. commun.) inhibited by 53% HIV replication in unstimu- 
lated normal B lymphocytes. When F97-6B3 and OKB7 were 
added simultaneously, inhibition reached 95% (data not shown) 
instead of 53 and 77%, respectively, suggesting that both 
SCR1-2 and SCR 5-8 are involved in HIV-CD21 interactions, 
or that binding of mAb to SCR 5-8 inhibits the link between 
CD35 and CD21. On B cells, CD21 does not work alone, it is 
associated either with CD19 or with CD35 molecules [31]. As 
our previous data have shown that addition of CD19 Ab nei- 
ther inhibited viral entry, when added alone, nor increased 
CD21-mediated inhibition [8], it seems likely that HIV interacts 
with CD21/CD35-associated molecules. In addition, the obser- 
vation that F97-6B3 mAb inhibited virus entry as well as OKB7 
Ab suggests that other sites than SRC 1 and 2 are involved in 
the interactions between HIV and CRs. Inhibition of opsonized 
HIV infection by CD21 reagents have also been described in 
T cell lines [18,28], B cell lines [22-24] and thymocytes [25]. On 
B cell lines, Tremblay et al. [22] have obtained a complete 
inhibition of the C'-ADE HIV infection with OKB7 whereas 
this antibody only induced a partial one in our normal B cells. 
In these cells as well as in thymocytes [32], CD35 synergize with 
CD21 for the blocking of HIV entry. As CD35 may function 
as a cofactor for the cleavage of iC3b into C3dg, a ligand for 
CD21 [9], inhibition of HIV infection would result from a 
deficit in C3 cleavage. From data on HIV infection of HPB- 
ALL T cells, it seems more likely that CD35 functions as a 
receptor for opsonized HIV [32]. This hypothesis i  strength- 
ened by data on monocytes showing that blockade of CD35 on 
CD35 high primary monocytes allowed a total inhibition of op- 
sonized virus entry [21] and suggesting that the role of CD35 
as HIV receptor would be particularly important in the absence 
of CD21. 
With CD4-negative B lymphocytes, independent CD21- or 
CD35-blocking is more efficient han with CD4 dim B lympho- 
cytes (Fig. 2A). In this case, contribution of CD4 molecule is 
minimal since no additive effect of CD4 mAb was observed, 
demonstrating that CD21 and CD35 are indeed an alternate 
pathway for normal B lymphocyte infection by opsonized HIV. 
Nevertheless, as with CD4-blocking, no total inhibition was 
reached by their simultaneous blocking. We, thus, performed 
blockade of both CRs and CD4 pathways. Results howed that 
inhibition was extremely important but not total, particularly 
in 2-day stimulated B lymphocytes ( ee Fig. 2B), suggesting 
another putative CD4- and CRs-independent process for HIV 
entry. Curtis et al. have showed that a C-type lectin which 
normally binds mannose is able to bind the glycosylated enve- 
lope glycoprotein gpl20 with high affinity [33]. Once bound to 
the lectin, gp120 is rapidly internalized, suggesting that C-type 
lectin might mediate cell infection by a CD4-independent mech- 
anism. Since no monoclonal antibodies to the mannose-binding 
site of this lectin were available, we used 2 concentrations of
mannose (10 and 100/lg/ml) to compete with the possible bind- 
ing of HIV. Whatever the mannose concentration, o signifi- 
cant inhibition of infection was obtained (data not shown), 
suggesting that either C-type lectin is absent from the B cell 
surface or that lectin plays a marginal role in HIV entry in these 
cells. 
In the present study, we showed that CD4 and CRI/CR2 are 
the main pathways for HIV entry in normal B cells exposed to 
opsonized virus. As these results have been obtained with the 
HIV-1/Lai strain, it would be interesting to test whether these 
2 pathways are similarly used by clinical isolates of the virus, 
opsonized by autologous patient's antibodies. Nevertheless, 
our HIV-1/Lai stock has always been grown in primary human 
cells, and was then never selected for cell line infection capacity. 
Our results are, consequently, not subjected to this possible 
bias. It is worth noting that, while opsonized, the virus entry 
in normal B cells used both CD4 and CRs. This suggests that, 
in lymphoid organs which constitute a major site of intense viral 
replication [34] and where the virus is mainly present as immune 
complexes (virus opsonized by both anti-HIV antibodies and 
complement) at the surface of follicular dendritic cells, HIV 
would enter in B cells through similar mechanisms. As follicular 
dendritic ells are located in germinal centers of lymphoid or- 
gans, one can speculate that GC B cells will be particularly 
sensitive to HIV infection. Although CD21 and CD35 expres- 
sion decrease with B cell activation, GC B cells still express 
important levels of both antigens, whereas in vivo infection of 
lymphoid organ B cells is infrequently detected. This discrep- 
ancy would suggest hat, once infected, B lymphocytes are 
unable to normally interact with their microenvironment, and 
die. We feel that our in vitro infection model will help us to 
evaluate this hypothesis. 
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